Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Daniel M. Hartung, PharmD, MPH
Advertisement
Articles by Daniel M. Hartung, PharmD, MPH
Little is known about opioid prescribing patterns in patients with chronic overlapping pain conditions. This study suggests target populations for interventions to manage chronic pain.
Advertisement
Latest Updated Articles
Budget Impact Analysis of Biosimilar Natalizumab in the USPublished: May 17th 2024 | Updated:
- Chronic Overlapping Pain Conditions and Long-term Opioid Treatment
Published: May 17th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Contributor: American Patients vs Foreign Governments—A Tale of 2 Value Sets
2
Asundexian Cuts Recurrent Stroke Risk Without More Bleeding: Mukul Sharma, MD, MSc
3
FDA Approves First-in-Class Optune Pax Device for Pancreatic Cancer
4
Bipartisan Break Up Big Medicine Act Targets Vertical Integration in Health Care
5